TARGETING DNA DAMAGE RESPONSE
At the Forefront of Emerging Concepts & Strategies
Sunday, April 2, 2017 • 6:30 PM - 9:00 PM
Renaissance Washington, DC Hotel

Bibliography & Suggested Reading


Domchek SM, Hendifard AE, McWilliams RR, et al. RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation. Presented at the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 4110.


Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.

Klein AP. Identifying people at a high risk of developing pancreatic cancer.

Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective.

Jiricny J. The multifaceted mismatch-repair system.

Jackson SP, Helleday T. DNA REPAIR. Drugging DNA repair.

Hustedt N, Durocher D. The control of DNA repair by the cell cycle.

phase II consortium trial. Presented at the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, IL. Abstract 5010.

prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)—A University of Chicago

Hussain M, Carducci MA, Slovin S, et al. Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone +


Hussein M, Carducci MA, Slovin S, et al. Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)—A University of Chicago phase II consortium trial. Presented at the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, IL. Abstract 5010.


Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.


